![](/img/cover-not-exists.png)
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
Salloway, Stephen, Honigberg, Lee A., Cho, William, Ward, Michael, Friesenhahn, Michel, Brunstein, Flavia, Quartino, Angelica, Clayton, David, Mortensen, Deborah, Bittner, Tobias, Ho, Carole, Rabe, ChVolume:
10
Language:
english
Journal:
Alzheimer's Research & Therapy
DOI:
10.1186/s13195-018-0424-5
Date:
December, 2018
File:
PDF, 1.53 MB
english, 2018